Achaogen’s bankruptcy and going-out-of-business sale offer a grim cautionary tale for the future of antibiotic development

The lights are winking out at Achaogen, offering another cautionary tale that will make it even less likely we’ll see new companies come along to develop antibiotics — even as drug-resistant strains of bacteria pose a rising threat to the world’s population.